Bod Science's share price has continued climbing after the company confirmed that all 198 participants enrolled in its phase II clinical trial have finished their course of treatment.
The stock rose a further 3.5% to $0.089c, extending a run that has seen shares gain 78% over the past month, driven by developments in the company's over-the-counter clinical trial and pharmacokinetics studies tied to its Aqua Phase technology.
Even so, the stock remains well short of the 52-week high of $0.17c recorded in December.
Now that the Can-Rest clinical trial — which assessed Bod's CBD soft-gel capsule as a treatment for insomnia — has wrapped up, researchers will move to data analysis, with top-line results expected in August.
A positive outcome would underpin Bod's application to register an over-the-counter CBD product with the Therapeutic Goods Administration.
Provided the results are favourable, a submission dossier is anticipated to be filed with the TGA in the final quarter of 2023.
The trial was conducted by the Woolcock Institute of Medical Research, a specialist sleep research organisation.
Bod Science chief executive Jo Patterson said she was "thrilled" to have reached the milestone.
"The now-completed clinical trial is the only advanced schedule 3 CBD product candidate for the Australian market," she said. "We look forward to receiving the results of the study next month."
